Penn’s School of Medicine has been tapped to receive a $10 million grant to support academic research from GlaxoSmithKline (GSK), the Philadelphia-based pharmaceutical company. According to Dr. Arthur Rubenstein, dean of the school and Penn’s executive vice president for the Health System, the unrestricted grant will “permit our researchers to continue to aggressively pursue the translational nature of our work—which seeks to transform knowledge gained at the benchside into safe and effective therapies and treatments that improve patient care.”
Dr. Tachi Yamada, GSK’s chairman of research and development, added: “We are hopeful that this grant will further the important research being done at Penn and facilitate scientific interchange between its scientists and our own.”
